Skip to content

The intervention effect of internet-based smart healthcare on cardiovascular metabolic risk factors in patients with hypertension

The intervention effect of internet-based smart healthcare on cardiovascular metabolic risk factors in patients with hypertension

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600126637
Enrollment
Unknown
Registered
2026-06-12
Start date
2026-04-15
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, cardiovascular and metabolic chronic diseases, obesity, hyperlipidemia, diabetes, hyperacidemia

Interventions

Research Group:Standard treatment + intervention via a smart management platform
Control group:Standard treatment + routine outpatient follow-up

Sponsors

The First Affiliated Hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with a confirmed diagnosis of primary hypertension who also have at least one of the following metabolic abnormalities: type 2 diabetes, impaired glucose tolerance, or impaired fasting glucose; dyslipidemia (including hypercholesterolemia, hypertriglyceridemia, and low HDL cholesterol); hyperuricemia; obesity (BMI >= 28 kg/m²; or waist circumference >= 90 cm [men] and >= 85 cm [women]; or waist-to-hip ratio [WHR] >= 0.90 [men] and >= 0.85 [women]). 2. Age 18–75 years (inclusive). 3. Able to perform relevant tasks using a mobile phone or computer independently or with family assistance. 4. Willing to participate in this study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Confirmed history of coronary artery disease (history of myocardial infarction; severe coronary artery stenosis identified by coronary CT or angiography); 2. Acute or chronic cerebrovascular disease; 3. Acute heart failure or acute exacerbation of chronic heart failure; 4. Severe hepatic or renal insufficiency (eGFR 5 times the upper limit of normal); 5. Malignant tumors; 6. Pregnant or breastfeeding women.

Design outcomes

Primary

MeasureTime frame
Adherence to Hypertension Treatment;systolic blood pressure;Fasting blood glucose;Blood lipids;

Secondary

MeasureTime frame
Weight;BMI;Waist and hip measurements;

Countries

China

Contacts

Public ContactYan Liu

The First Affiliated Hospital of Dalian Medical University

15541191236@163.com+86 180 9887 5820

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026